Bicara Therapeutics

Recent news

• Rating change
  Analysts Are Bullish on Top NA Stocks: Veradermics, Incorporated (MANE), Bicara Therapeutics Inc. (BCAX)
  TipRanks · 2026/8/12
• Rating change
  Morgan Stanley Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $37
  Market Newswire · 2026/8/12
• Analysts Conflicted on These NA Names: Bicara Therapeutics Inc. (BCAX), CoreWeave (CRWV) and Cardinal Infrastructure Group, Inc. (CDNL)
  TipRanks · 2026/8/12
• Rating change
  BofA Securities Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Announces Target Price $34
  Market Newswire · 2026/8/12
• Rating change
  BTIG Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Raises Target Price to $39
  Market Newswire · 2026/8/12
• Rating change
  Bicara Therapeutics Inc. (BCAX) Gets a Hold From Wells Fargo
  TipRanks · 2026/6/2
• Mizuho Securities Reaffirms Their Hold Rating on Bicara Therapeutics Inc. (BCAX)
  TipRanks · 2026/8/13
• Rating change
  BofA Securities Maintains Bicara Therapeutics(BCAX.US) With Buy Rating
  Market Newswire · 2026/6/2
• Rating change
  Analysts Offer Insights on NA Companies: Enhanced Group (ENHA), MNTN, Inc Class A (MNTN) and Bicara Therapeutics Inc. (BCAX)
  TipRanks · 2026/8/12
• Rating change
  Wedbush Reaffirms Their Buy Rating on Bicara Therapeutics Inc. (BCAX)
  TipRanks · 2026/8/13
• Rating change
  Goldman Sachs Keeps Their Hold Rating on Bicara Therapeutics Inc. (BCAX)
  TipRanks · 2026/6/2
• Rating change
  Analysts' Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Bicara Therapeutics Inc. (BCAX)
  TipRanks · 2026/6/2
• BMO Capital Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $35
  Market Newswire · 2026/10/7
• Rating change
  Analysts Have Conflicting Sentiments on These NA Companies: Bending Spoons (BSP), EToro (ETOR) and Bicara Therapeutics Inc. (BCAX)
  TipRanks · 2026/8/12
• Stifel Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Cuts Target Price to $45
  Market Newswire · 2026/8/14
• Rating change
  BTIG Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $28
  Market Newswire · 2026/7/28
• Rating change
  Wedbush Remains a Buy on Bicara Therapeutics Inc. (BCAX)
  TipRanks · 2026/5/27
• Rating change
  H.C. Wainwright Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $42
  Market Newswire · 2026/6/1
• Rating change
  Analysts Offer Insights on NA Companies: Smithfield Foods (SFD), Bicara Therapeutics Inc. (BCAX) and Concentra Group Holdings Parent, Inc. (CON)
  TipRanks · 2026/8/12
• JonesTrading Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $30
  Market Newswire · 2026/9/8

Headlines are aggregated automatically and are not independently verified or edited by our team.